

## **8. Literaturverzeichnis**

AGHAJANIAN GK und VANDERMAELEN CP. Intracellular recordings from serotonergic dorsal raphe neurons: Pacemaker potentials and the effect of LSD. *Brain Res*, 238: 463-9, 1982.

AGREN H. Symptom patterns in unipolar and bipolar depression correlating with monoamine metabolites in the cerebrospinal fluid: II. Suicide. *Psychiatry Res*, 3: 225-36, 1980.

AGREN H, OSTERBERG B, und FRANZEN O. Depression and somatosensory evoked potentials: II. Correlations between SEP and depressive phenomenology. *Biol Psychiatry*, 18: 651-9, 1983a.

AGREN H, OSTERBERG B, NIKLASSON F, und FRANZEN O. Depression and somatosensory evoked potentials: I. Correlations between SEP and monoamine and purine metabolites in CSF. *Biol Psychiatry*, 18: 635-49, 1983b.

AMBROSINI A, ROSSI P, DE PASQUA V, PIERELLI F, und SCHOENEN J. Lack of habituation causes high intensity dependence of auditory evoked cortical potentials in migraine. *Brain*, 126: 2009-15, 2003.

AREZZO J, PICKOFF A, und VAUGHAN HG, JR. The sources and intracerebral distribution of auditory evoked potentials in the alert rhesus monkey. *Brain Res*, 90: 57-73, 1975.

ASBERG M, ERIKSSON B, MARTENSSON B, TRASKMAN-BENDZ L, und WAGNER A. Therapeutic effects of serotonin uptake inhibitors in depression. *J Clin Psychiatry*, 47 Suppl: 23-35, 1986.

ASBERG M, THOREN P, TRASKMAN L, BERTILSSON L, und RINGBERGER V. "Serotonin depression"--a biochemical subgroup within the affective disorders? *Science*, 191: 478-80, 1976a.

ASBERG M, TRASKMAN L, und THOREN P. 5-HIAA in the cerebrospinal fluid. A biochemical suicide predictor? *Arch Gen Psychiatry*, 33: 1193-7, 1976b.

ATTENBURROW MJ, MITTER PR, WHALE R, TERAO T, und COWEN PJ. Low-dose citalopram as a 5-HT neuroendocrine probe. *Psychopharmacology (Berl)*, 155: 323-6, 2001.

BAKISH D, CAVAZZONI P, CHUDZIK J, RAVINDRAN A, und HRDINA PD. Effects of selective serotonin reuptake inhibitors on platelet serotonin parameters in major depressive disorder. *Biol Psychiatry*, 41: 184-90, 1997.

BANKI CM und ARATO M. Amine metabolites and neuroendocrine responses related to depression and suicide. *J Affect Disord*, 5: 223-32, 1983.

BANKI CM, MOLNAR G, und FEKETE I. Correlation of individual symptoms and other clinical variables with cerebrospinal fluid amine metabolites and tryptophan in depression. *Arch Psychiatr Nervenkr*, 229: 345-53, 1981.

BARRATT ES, PRITCHARD WS, FAULK DM, und BRANDT ME. The relationship between impulsiveness subtraits, trait anxiety, and visual N100 augmenting/reducing: A topographic analysis. *Person Individ Diff*, 8: 43-51, 1987.

BECK AT, WARD CH, MENDELSON M, MOCK J, und ERBAUGH J. An inventory for measuring depression. *Arch Gen Psychiatry*, 4: 561-71, 1961.

BENKERT O und HIPPIUS. Kompendium der Psychiatrischen Pharmakotherapie. *Berlin: Springer*, 2003.

BENTURQUIA N, COUDERC F, SAUVINET V, ORSET C, PARROT S, BAYLE C, RENAUD B, und DENOROY L. Analysis of serotonin in brain microdialysates using capillary electrophoresis and native laser-induced fluorescence detection. *Electrophoresis*, 26: 1071-9, 2005.

BENWELL ME und BALFOUR DJ. The effects of nicotine administration on 5-HT uptake and biosynthesis in rat brain. *Eur J Pharmacol*, 84: 71-7, 1982.

BENWELL ME, BALFOUR DJ, und ANDERSON JM. Smoking-associated changes in the serotonergic systems of discrete regions of human brain. *Psychopharmacology (Berl)*, 102: 68-72, 1990.

BIRKMAYER W und RIEDERER P. Biochemical post-mortem findings in depressed patients. *J Neural Transm*, 37: 95-109, 1975.

BLOOM FE. What is the role of general activating systems in cortical function? In: Rakic P, Singer W (eds). *Neurobiology of neocortex (Dahlem Workshop)*, Chichester, Wiley: 407-421, 1988.

BOSKER FJ, CREMERS TI, JONGSMA ME, WESTERINK BH, WIKSTROM HV, und DEN BOER JA. Acute and chronic effects of citalopram on postsynaptic 5-hydroxytryptamine(1A) receptor-mediated feedback: A microdialysis study in the amygdala. *J Neurochem*, 76: 1645-53, 2001.

BOWEN DM, ALLEN SJ, BENTON JS, GOODHARDT MJ, HAAN EA, PALMER AM, SIMS NR, SMITH CC, SPILLANE JA, ESIRI MM, NEARY D, SNOWDON JS, WILCOCK GK, und DAVISON AN. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. *J Neurochem*, 41: 266-72, 1983.

BRANCHEY L, BRANCHEY M, SHAW S, und LIEBER CS. Depression, suicide, and aggression in alcoholics and their relationship to plasma amino acids. *Psychiatry Res*, 12: 219-26, 1984a.

BRANCHEY L, BRANCHEY M, SHAW S, und LIEBER CS. Relationship between changes in plasma amino acids and depression in alcoholic patients. *Am J Psychiatry*, 141: 1212-5, 1984b.

BREWERTON TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. *Psychoneuroendocrinology*, 20: 561-90, 1995.

BRUNNER E, DOMHOF S, und LANGER F. Nonparametric analysis of longitudinal data in factorial experiments. *New York: Wiley*, 2002.

BUCHSBAUM M. Individual differences in stimulus intensity response. *Psychophysiology*, 8: 600-11, 1971.

BUCHSBAUM M, GILLIN JC, und PFEFFERBAUM A. Effect of sleep stage and stimulus intensity on auditory average evoked responses. *Psychophysiology*, 12: 707-12, 1975.

BUCHSBAUM M und SILVERMAN J. Stimulus intensity control and the cortical evoked response. *Psychosom Med*, 30: 12-22, 1968.

BUCHSBAUM MS, VAN KAMMEN DP, und MURPHY DL. Individual differences in average evoked responses to D- and L-amphetamine with and without lithium carbonate in depressed patients. *Psychopharmacology (Berl)*, 51: 129-35, 1977.

CARPENTER LL, ANDERSON GM, PELTON GH, GUDIN JA, KIRWIN PD, PRICE LH, HENINGER GR, und McDOUGLE CJ. Tryptophan depletion during continuous CSF sampling in healthy human subjects. *Neuropsychopharmacology*, 19: 26-35, 1998.

CARRILLO-DE-LA-PENA MT. ERP augmenting/reducing and sensation seeking: A critical review. *Int J Psychophysiol*, 12: 211-20, 1992.

CARRILLO-DE-LA-PENA MT. Effects of intensity and order of stimuli presentation on AEPs: An analysis of the consistency of EP augmenting/reducing in the auditory modality. *Clin Neurophysiol*, 110: 924-32, 1999.

CEULEMANS DLS, VAN DOREN J, NUYTS J, und DE WIT P. Therapeutic efficacy of serotonin and dopamine antagonism on positive and negative symptoms of chronic schizophrenic patients. *Fourth World Congress of Biological Psychiatry*: 272, 1985.

COCCARO EF. Central serotonin and impulsive aggression. *Br J Psychiatry Suppl*: 52-62, 1989.

COCCARO EF, GABRIEL S, und SIEVER LJ. Buspirone challenge: Preliminary evidence for a role for central 5-HT<sub>1A</sub> receptor function in impulsive aggressive behavior in humans. *Psychopharmacol Bull*, 26: 393-405, 1990.

COCCARO EF, SIEVER LJ, KLAR HM, MAURER G, COCHRANE K, COOPER TB, MOHS RC, und DAVIS KL. Serotonergic studies in patients with affective and personality disorders. Correlates with suicidal and impulsive aggressive behavior. *Arch Gen Psychiatry*, 46: 587-99, 1989.

COLADO MI, GRANADOS R, O'SHEA E, ESTEBAN B, und GREEN AR. The acute effect in rats of 3,4-methylenedioxyethamphetamine (MDEA, "eve") on body temperature and long term degeneration of 5-HT neurones in brain: A comparison with MDMA ("ecstasy"). *Pharmacol Toxicol*, 84: 261-6, 1999.

CONNOLLY JF und GRUZELIER JH. Amplitude and latency changes in the visual evoked potential to different stimulus intensities. *Psychophysiology*, 19: 599-608, 1982.

CONNOLLY JF und GRUZELIER JH. Persistent methodological problems with evoked potential augmenting-reducing. *Int J Psychophysiol*, 3: 299-306, 1986.

CROFT RJ, KLUGMAN A, BALDEWEG T, und GRUZELIER JH. Electrophysiological evidence of serotonergic impairment in long-term MDMA ("ecstasy") users. *Am J Psychiatry*, 158: 1687-92, 2001.

CROSS AJ, CROW TJ, FERRIER IN, JOHNSON JA, BLOOM SR, und CORSELLIS JA. Serotonin receptor changes in dementia of the Alzheimer type. *J Neurochem*, 43: 1574-81, 1984.

CURRAN HV und LADER M. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. *Eur J Clin Pharmacol*, 29: 601-7, 1986.

DEBENER S, STROBEL A, KURSCHNER K, KRANCZIOCH C, HEBENSTREIT J, MAERCKER A, BEAUDUCEL A, und BROCKE B. Is auditory evoked potential augmenting/reducing affected by acute tryptophan depletion? *Biol Psychol*, 59: 121-33, 2002.

DI S und BARTH DS. The functional anatomy of middle-latency auditory evoked potentials: Thalamocortical connections. *J Neurophysiol*, 68: 425-31, 1992.

DIERKS T, BARTA S, DEMISCH L, SCHMECK K, ENGLERT E, KEWITZ A, MAURER K, und POUSTKA F. Intensity dependence of auditory evoked potentials (AEPs) as biological marker for cerebral serotonin levels: Effects of tryptophan depletion in healthy subjects. *Psychopharmacology (Berl)*, 146: 101-7, 1999.

DONOGHUE JP und CARROLL KL. Cholinergic modulation of sensory responses in rat primary somatic sensory cortex. *Brain Res*, 408: 367-71, 1987.

FIGUERAS G, PEREZ V, SAN MARTINO O, ALVAREZ E, und ARTIGAS F. Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de trastornos afectivos. *Biol Psychiatry*, 46: 518-24, 1999.

FOOTE SL und MORRISON JH. Extrathalamic modulation of cortical function. *Annu Rev Neurosci*, 10: 67-95, 1987.

FRANKLE WG, HUANG Y, HWANG DR, TALBOT PS, SLIFSTEIN M, VAN HEERTUM R, ABIDARGHAM A, und LARUELLE M. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-MCN 5652 in healthy humans. *J Nucl Med*, 45: 682-94, 2004.

GALLINAT J, KUNZ D, LANG UE, KALUS P, JUCKEL G, EGGERS J, MAHLBERG R, STAEDTGEN M, WERNICKE C, ROMMELSPACHER H, und SMOLKA MN. Serotonergic effects of smoking are independent from the human serotonin transporter gene promoter polymorphism: Evidence from auditory cortical stimulus processing. *Pharmacopsychiatry*, 38: 158-60, 2005.

GIBBONS RD und DAVIS JM. Consistent evidence for a biological subtype of depression characterized by low CSF monoamine levels. *Acta Psychiatr Scand*, 74: 8-12, 1986.

GOTTFRIES CG, VON KNORRING L, und PERRIS C. Neurophysiological measures related to levels of 5-hydroxyindoleacetic acid, homovanillic acid and tryptophan in cerebrospinal fluid of psychiatric patients. *Neuropsychobiology*, 2: 1-8, 1976.

GUNDLAH C, HJORTH S, und AUERBACH SB. Autoreceptor antagonists enhance the effect of the reuptake inhibitor citalopram on extracellular 5-HT: This effect persists after repeated citalopram treatment. *Neuropharmacology*, 36: 475-82, 1997.

HALL GH. Effects of nicotine and tobacco smoke on the electrical activity of the cerebral cortex and olfactory bulb. *Br J Pharmacol*, 38: 271-86, 1970.

HALL RA, RAPPAPORT M, HOPKINS HK, und GRIFFIN R. Tobacco and evoked potential. *Science*, 180: 212-4, 1973.

HARI R, AITTONIEMI K, JARVINEN ML, KATILA T, und VARPULA T. Auditory evoked transient and sustained magnetic fields of the human brain. Localization of neural generators. *Exp Brain Res*, 40: 237-40, 1980.

HEGERL U. Neurophysiologische Untersuchungen in der Psychiatrie. *Wien: Springer*, 1998.

HEGERL U, GALLINAT J, und MROWINSKI D. Intensity dependence of auditory evoked dipole source activity. *Int J Psychophysiol*, 17: 1-13, 1994.

HEGERL U, HERRMANN WM, ULRICH G, und MULLER-OERLINGHAUSEN B. Effects of lithium on auditory evoked potentials in healthy subjects. *Biol Psychiatry*, 27: 555-60, 1990.

HEGERL U und JUCKEL G. Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: A new hypothesis. *Biol Psychiatry*, 33: 173-87, 1993.

HEGERL U und JUCKEL G. Identifying psychiatric patients with serotonergic dysfunctions by event-related potentials. *World J Biol Psychiatry*, 1: 112-8, 2000.

HEGERL U, LIPPERHEIDE K, JUCKEL G, SCHMIDT LG, und ROMMELSPACHER H. Antisocial tendencies and cortical sensory-evoked responses in alcoholism. *Alcohol Clin Exp Res*, 19: 31-6, 1995.

HEINZ A, HIGLEY JD, GOREY JG, SAUNDERS RC, JONES DW, HOMMER D, ZAJICEK K, SUOMI SJ, LESCH KP, WEINBERGER DR, und LINNOILA M. In vivo association between alcohol intoxication, aggression, and serotonin transporter availability in nonhuman primates. *Am J Psychiatry*, 155: 1023-8, 1998.

HENINGER GR, DELGADO PL, und CHARNEY DS. The revised monoamine theory of depression: A modulatory role for monoamines, based on new findings from monoamine depletion experiments in humans. *Pharmacopsychiatry*, 29: 2-11, 1996.

HESSE S, BARTHEL H, MURAI T, MULLER U, MULLER D, SEESE A, KLUGE R, und SABRI O. Is correction for age necessary in neuroimaging studies of the central serotonin transporter? *Eur J Nucl Med Mol Imaging*, 30: 427-30, 2003.

HUBBARD RB, JUDD LL, HUEY LY, KRIPKE DF, JANOWSKY DS, und LEWIS AS. Visual cortical evoked potentials in alcoholics and normals maintained on lithium carbonate: Augmentation and reduction phenomena. *Adv Exp Med Biol*, 126: 573-7, 1980.

HÜTHER G und RÜTHER E. Das Serotonerge System. *Bremen: Uni-Med.*, 2000.

IACONO WG, GABBAY FH, und LYKKEN DT. Measuring the average evoked response to light flashes: The contribution of eye-blink artifact to augmenting-reducing. *Biol Psychiatry*, 17: 897-911, 1982.

JACOBS BL. Single unit activity of locus coeruleus neurons in behaving animals. *Prog Neurobiol*, 27: 183-94, 1986.

JACOBS BL und AZMITIA EC. Structure and function of the brain serotonin system. *Physiol Rev*, 72: 165-229, 1992.

JACOBS BL, FORNAL CA, und WILKINSON LO. Neurophysiological and neurochemical studies of brain serotonergic neurons in behaving animals. *Ann N Y Acad Sci*, 600: 260-8; discussion 268-71, 1990.

JAMES L, GORDON E, KRAIUHIN C, HOWSON A, und MEARES R. Augmentation of auditory evoked potentials in somatization disorder. *J Psychiatr Res*, 24: 155-63, 1990.



JASPERS K. The physician in the technical age. *Klin Wochenschr*, 36: 1037-43, 1958.

JAVITT DC, SCHROEDER CE, STEINSCHNEIDER M, AREZZO JC, RITTER W, und VAUGHAN HG, JR. Cognitive event-related potentials in human and non-human primates: Implications for the PCP/NMDA model of schizophrenia. *Electroencephalogr Clin Neurophysiol Suppl*, 44: 161-75, 1995.

JOYCE PR und PAYKEL ES. Predictors of drug response in depression. *Arch Gen Psychiatry*, 46: 89-99, 1989.

JUCKEL G. Serotonin und akustisch evozierte Potentiale. *Darmstadt: Steinkopff*, 2005.

JUCKEL G, CSEPE V, MOLNAR M, HEGERL U, und KARMOS G. Intensity dependence of auditory evoked potentials in behaving cats. *Electroencephalogr Clin Neurophysiol*, 100: 527-37, 1996.

JUCKEL G, GALLINAT J, RIEDEL M, SOKULLU S, SCHULZ C, MOLLER HJ, MULLER N, und HEGERL U. Serotonergic dysfunction in schizophrenia assessed by the loudness dependence measure of primary auditory cortex evoked activity. *Schizophr Res*, 64: 115-24, 2003.

JUCKEL G, HEGERL U, MOLNAR M, CSEPE V, und KARMOS G. Auditory evoked potentials reflect serotonergic neuronal activity--a study in behaving cats administered drugs acting on 5-HT<sub>1A</sub> autoreceptors in the dorsal raphe nucleus. *Neuropsychopharmacology*, 21: 710-6, 1999.

JUCKEL G, MOLNAR M, HEGERL U, CSEPE V, und KARMOS G. Auditory-evoked potentials as indicator of brain serotonergic activity--first evidence in behaving cats. *Biol Psychiatry*, 41: 1181-95, 1997.

JUCKEL G, SCHMIDT LG, ROMMELSPACHER H, und HEGERL U. The tridimensional personality questionnaire and the intensity dependence of auditory evoked dipole source activity. *Biol Psychiatry*, 37: 311-7, 1995.

KÄHKÖNEN S, AHVENINEN J, PENNANEN S, LIESIVUORI J, ILMONIEMI RJ, und JAASKELAINEN IP. Serotonin modulates early cortical auditory processing in healthy subjects: Evidence from MEG with acute tryptophan depletion. *Neuropsychopharmacology*, 27: 862-8, 2002a.

KÄHKÖNEN S, JAASKELAINEN IP, PENNANEN S, LIESIVUORI J, und AHVENINEN J. Acute tryptophan depletion decreases intensity dependence of auditory evoked magnetic N1/P2 dipole source activity. *Psychopharmacology (Berl)*, 164: 221-7, 2002b.

KAHN RS, KALUS O, WETZLER S, CAHN W, ASNIS GM, und VAN PRAAG HM. Effects of serotonin antagonists on m-chlorophenylpiperazine-mediated responses in normal subjects. *Psychiatry Res*, 33: 189-98, 1990.

KANE J, HONIGFELD G, SINGER J, und MELTZER H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. *Arch Gen Psychiatry*, 45: 789-96, 1988.

KAPFFHAMMER H. Somatoforme Störungen. In: Möller HJ, Kapfhammer HP (eds): *Psychiatrie und Psychotherapie. Berlin: Springer*. 1303-1385, 2000.

KAPITANY T, SCHINDL M, SCHINDLER SD, HESSELMANN B, FUREDER T, BARNAS C, SIEGHART W, und KASPER S. The citalopram challenge test in patients with major depression and in healthy controls. *Psychiatry Res*, 88: 75-88, 1999.

KNIGHT RT, HILLYARD SA, WOODS DL, und NEVILLE HJ. The effects of frontal and temporal-parietal lesions on the auditory evoked potential in man. *Electroencephalogr Clin Neurophysiol*, 50: 112-24, 1980.

KNIGHT RT, SCABINI D, WOODS DL, und CLAYWORTH C. The effects of lesions of superior temporal gyrus and inferior parietal lobe on temporal and vertex components of the human AEP. *Electroencephalogr Clin Neurophysiol*, 70: 499-509, 1988.

KNOTT VJ und VENABLES PH. Stimulus intensity control and the cortical evoked response in smokers and non-smokers. *Psychophysiology*, 15: 186-92, 1978.

KUGAYA A, SANACORA G, STALEY JK, MALISON RT, BOZKURT A, KHAN S, ANAND A, VAN DYCK CH, BALDWIN RM, SEIBYL JP, CHARNEY D, und INNIS RB. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. *Biol Psychiatry*, 56: 497-502, 2004.

LARISCH R, KLIMKE A, MAYORAL F, HAMACHER K, HERZOG HR, VOSBERG H, TOSCH M, GAEBEL W, RIVAS F, COENEN HH, und MULLER-GARTNER HW. Disturbance of serotonin 5HT<sub>2</sub> receptors in remitted patients suffering from hereditary depressive disorder. *Nuklearmedizin*, 40: 129-34, 2001.

LAWLOR BA, SUNDERLAND T, MELLOW AM, HILL JL, NEWHOUSE PA, und MURPHY DL. A preliminary study of the effects of intravenous m-chlorophenylpiperazine, a serotonin agonist, in elderly subjects. *Biol Psychiatry*, 25: 679-86, 1989.

LEIBOWITZ SF. Neurochemical-neuroendocrine systems in the brain controlling macronutrient intake and metabolism. *Trends Neurosci*, 15: 491-7, 1992.

LESCH KP und MÖSSNER R. Inactivation of 5HT transport in mice: Modeling altered 5HT homeostasis implicated in emotional dysfunction, affective disorders, and somatic syndromes. *Handb Exp Pharmacol*: 417-56, 2006.

LEWIS DA, CAMPBELL MJ, FOOTE SL, und MORRISON JH. The monoaminergic innervation of primate neocortex. *Hum Neurobiol*, 5: 181-8, 1986.

LEWIS DA und MCCHESENEY C. Tritiated imipramine binding distinguishes among subtypes of depression. *Arch Gen Psychiatry*, 42: 485-8, 1985.

LEYSEN JE, VAN GOMPEL P, GOMMEREN W, WOESTENBORGHES R, und JANSSEN PA. Down regulation of serotonin-S<sub>2</sub> receptor sites in rat brain by chronic treatment with the serotonin-S<sub>2</sub> antagonists: ritanserin and setoperone. *Psychopharmacology (Berl)*, 88: 434-44, 1986.

LEYTON M, YOUNG SN, PIHL RO, ETEZADI S, LAUZE C, BLIER P, BAKER GB, und BENKELFAT C. A comparison of the effects of acute tryptophan depletion and acute

phenylalanine/tyrosine depletion in healthy women. *Adv Exp Med Biol*, 467: 67-71, 1999.

LIEGEOIS-CHAUVEL C, MUSOLINO A, BADIÉ JM, MARQUIS P, und CHAUVEL P. Evoked potentials recorded from the auditory cortex in man: Evaluation and topography of the middle latency components. *Electroencephalogr Clin Neurophysiol*, 92: 204-14, 1994.

LINNOILA M, VIRKKUNEN M, SCHEININ M, NUUTILA A, RIMON R, und GOODWIN FK. Low cerebrospinal fluid 5-hydroxyindoleacetic acid concentration differentiates impulsive from nonimpulsive violent behavior. *Life Sci*, 33: 2609-14, 1983.

LOLAS F, COLLIN C, CAMPOSANO S, ETCHEBERRIGARAY R, und REES R. Hemispheric asymmetry of augmenting/reducing in visual and auditory evoked potentials. *Biol Psychiatry*, 22: 1413-6, 1987.

LÜLLMANN H und MOHR K. Pharmakologie und Toxikologie. *Stuttgart: Georg Thieme Verlag*, 1999.

MAERTENS DE NOORDHOUT A, WANG W, und SCHOENEN J. Clinical neurophysiology and neurotransmitters. *Cephalalgia*, 15: 301-9, 1995.

MANNEL M, MULLER-OERLINGHAUSEN B, CZERNIK A, und SAUER H. 5-HT brain function in affective disorder: D,L-fenfluramine-induced hormone release and clinical outcome in long-term lithium/carbamazepine prophylaxis. *J Affect Disord*, 46: 101-13, 1997.

MARTIN P, MASSOL J, SOUBRIE P, und PUECH AJ. Effects of triiodothyronine (T3) on the potentiation by antidepressants of L-5-hydroxytryptophan-induced head-twitches in mice. *Prog Neuropsychopharmacol Biol Psychiatry*, 13: 735-48, 1989.

MASSEY AE, MARSH VR, und McALLISTER-WILLIAMS RH. Lack of effect of tryptophan depletion on the loudness dependency of auditory event related potentials in healthy volunteers. *Biol Psychol*, 65: 137-45, 2004.

MCCANN UD, SZABO Z, SCHEFFEL U, DANNALS RF, und RICAURTE GA. Positron emission tomographic evidence of toxic effect of MDMA ("ecstasy") on brain serotonin neurons in human beings. *Lancet*, 352: 1433-7, 1998.

MELTZER HY, ARORA RC, BABER R, und TRICOU BJ. Serotonin uptake in blood platelets of psychiatric patients. *Arch Gen Psychiatry*, 38: 1322-6, 1981.

MELTZER HY, LOWY MT, und KOENIG JI. The hypothalamic-pituitary-adrenal axis in depression. *Adv Biochem Psychopharmacol*, 43: 165-82, 1987.

MEYER JH, WILSON AA, GINOVRT N, GOULDING V, HUSSEY D, HOOD K, und HOULE S. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: A [(11)C]DASB PET imaging study. *Am J Psychiatry*, 158: 1843-9, 2001.

MITZDORF U. Current source-density method and application in cat cerebral cortex: Investigation of evoked potentials and EEG phenomena. *Physiol Rev*, 65: 37-100, 1985.

MOLLIVER ME, BERGER UV, MAMOUNAS LA, MOLLIVER DC, O'HEARN E, und WILSON MA. Neurotoxicity of MDMA and related compounds: Anatomic studies. *Ann N Y Acad Sci*, 600: 649-61; discussion 661-4, 1990.

MOORE P, LANDOLT HP, SEIFRITZ E, CLARK C, BHATTI T, KELSOE J, RAPAPORT M, und GILLIN JC. Clinical and physiological consequences of rapid tryptophan depletion. *Neuropsychopharmacology*, 23: 601-22, 2000.

MORRISON JH, FOOTE SL, MOLLIVER ME, BLOOM FE, und LIDOV HG. Noradrenergic and serotonergic fibers innervate complementary layers in monkey primary visual cortex: An immunohistochemical study. *Proc Natl Acad Sci U S A*, 79: 2401-5, 1982.

MURAKI I, INOUE T, HASHIMOTO S, IZUMI T, ITO K, und KOYAMA T. Effect of subchronic lithium treatment on citalopram-induced increases in extracellular concentrations of serotonin in the medial prefrontal cortex. *J Neurochem*, 76: 490-7, 2001.

NÄÄTÄNEN R und PICTON T. The N1 wave of the human electric and magnetic response to sound: A review and an analysis of the component structure. *Psychophysiology*, 24: 375-425, 1987.

NATHAN PJ, SEGRAVE R, PHAN KL, O'NEILL B, und CROFT RJ. Direct evidence that acutely enhancing serotonin with the selective serotonin reuptake inhibitor citalopram modulates the loudness dependence of the auditory evoked potential (LDAEP) marker of central serotonin function. *Hum Psychopharmacol*, 21: 47-52, 2006.

NEUMEISTER A, PIRKER W, WILLEIT M, PRASCHAK-RIEDER N, ASENBAUM S, BRUCKE T, und KASPER S. Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [<sup>123</sup>I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropine and single photon emission computed tomography. *Biol Psychiatry*, 47: 158-60, 2000.

NEUMEISTER A, PRASCHAK-RIEDER N, HESSELMANN B, TAUSCHER J, und KASPER S. The tryptophan depletion test. Basic principles and clinical relevance. *Nervenarzt*, 68: 556-62, 1997.

NINAN PT, VAN KAMMEN DP, SCHEININ M, LINNOILA M, BUNNEY WE, JR., und GOODWIN FK. CSF 5-hydroxyindoleacetic acid levels in suicidal schizophrenic patients. *Am J Psychiatry*, 141: 566-9, 1984.

NISHIZAWA S, BENKELFAT C, YOUNG SN, LEYTON M, MZENGEZA S, DE MONTIGNY C, BLIER P, und DIKSIC M. Differences between males and females in rates of serotonin synthesis in human brain. *Proc Natl Acad Sci U S A*, 94: 5308-13, 1997.

NORRA C. Experimental human challenge studies for central serotonergic system - investigation of neurophysiological and neuropsychological aspects. *Eur Arch Psychiatry Clin Neurosci*, 256: II/24, 2006.

NORRA C, MRAZEK M, TUCHTENHAGEN F, GOBBELE R, BUCHNER H, SASS H, und HERPERTZ SC. Enhanced intensity dependence as a marker of low serotonergic neurotransmission in borderline personality disorder. *J Psychiatr Res*, 37: 23-33, 2003.

PAPADOPOULOS GC und PARNAVELAS JG. Monoamine systems in the cerebral cortex: Evidence for anatomical specificity. *Prog Neurobiol*, 36: 195-200, 1991.

PAPANICOLAOU AC, BAUMANN S, ROGERS RL, SAYDJARI C, AMPARO EG, und EISENBERG HM. Localization of auditory response sources using magnetoencephalography and magnetic resonance imaging. *Arch Neurol*, 47: 33-7, 1990.

PATKAR AA, GOPALAKRISHNAN R, BERRETTINI WH, und WEINSTEIN SP. Differences in platelet serotonin transporter sites between african-american tobacco smokers and non-smokers. *Psychopharmacology (Berl)*, 166: 221-227, 2003.

PELIZZONE M, WILLIAMSON S, und KAUFMAN L. Evidence for multiple areas in the human auditory cortex. In: Weinberger H, Stroink G, Katila T (eds), *Biomagnetism: Applications and theory. Pergamon Press, New York*: 326-330, 1984.

PERRIN F, BERTRAND O, und PERNIER J. Early cortical somatosensory and N1 auditory evoked responses: Analysis with potential maps, scalp current density maps and three-concentric-shell head models. In: Mauerer K (ed) *Topographic brain mapping of EEG and evoked potentials. Berlin: Springer*: 390-395, 1989.

PERUGINI M, MAHONEY C, ILIVITSKY V, YOUNG SN, und KNOTT V. Effects of tryptophan depletion on acute smoking abstinence symptoms and the acute smoking response. *Pharmacology, Biochemistry and Behavior*, 74: 513-522, 2003.

PETRIE A. Some psychological aspects of pain and the relief of suffering. *Ann N Y Acad Sci*, 86: 13-27, 1960.

PHILLIPS KA, DWIGHT MM, und MCELROY SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. *J Clin Psychiatry*, 59: 165-71, 1998.

PINEDA JA, HOLMES TC, und FOOTE SL. Intensity-amplitude relationships in monkey event-related potentials: Parallels to human augmenting-reducing responses. *Electroencephalogr Clin Neurophysiol*, 78: 456-65, 1991.

PIRKER W, ASENBAUM S, HAUK M, KANDLHOFER S, TAUSCHER J, WILLEIT M, NEUMEISTER A, PRASCHAK-RIEDER N, ANGELBERGER P, und BRUCKE T. Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: Binding kinetics and effects of normal aging. *J Nucl Med*, 41: 36-44, 2000.

PIRKER W, ASENBAUM S, KASPER S, WALTER H, ANGELBERGER P, KOCH G, POZZERA A, DEECKE L, PODREKA I, und BRUCKE T. Beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. *J Neural Transm Gen Sect*, 100: 247-56, 1995.

PLETSCHER A (Ed.). Platelets as models for monoaminergic neurons. Essays in neurochemistry and neuropharmacology. *Chichester: John Wiley and Sons*, 1978.

POGARELL O, HAMANN C, POPPERL G, JUCKEL G, CHOUKER M, ZAUDIG M, RIEDEL M, MOLLER HJ, HEGERL U, und TATSCH K. Elevated brain serotonin transporter availability in patients with obsessive-compulsive disorder. *Biol Psychiatry*, 54: 1406-13, 2003.

PRESCOTT J, CONNOLLY JF, und GRUZELIER JH. The augmenting/reducing phenomenon in the auditory evoked potential. *Biol Psychol*, 19: 31-44, 1984.

PRITCHARD WS, BARRATT ES, FAULK DM, BRANDT ME, und BRYANT SG. Effects of phenytoin on N100 augmenting/reducing and the late positive complex of the event-related potential: A topographic analysis. *Neuropsychobiology*, 15: 201-7, 1986.

PROIETTI-CECCHINI A, AFRA J, und SCHOENEN J. Intensity dependence of the cortical auditory evoked potentials as a surrogate marker of central nervous system serotonin transmission in man: Demonstration of a central effect for the 5HT1B/1D agonist zolmitriptan (311C90, ZOMIG). *Cephalalgia*, 17: 849-54; discussion 799, 1997.

REILLY JG, MCTAVISH SF, und YOUNG AH. Rapid depletion of plasma tryptophan: A review of studies and experimental methodology. *J Psychopharmacol*, 11: 381-92, 1997.



REINIKAINEN KJ, PALJARVI L, HUUSKONEN M, SOININEN H, LAAKSO M, und RIEKKINEN PJ. A post-mortem study of noradrenergic, serotonergic and gabaergic neurons in Alzheimer's disease. *J Neurol Sci*, 84: 101-16, 1988.

REUBEN M und CLARKE PB. Nicotine-evoked [3H]5-hydroxytryptamine release from rat striatal synaptosomes. *Neuropharmacology*, 39: 290-9, 2000.

ROGERS RL, PAPANICOLAOU AC, BAUMANN SB, SAYDJARI C, und EISENBERG HM. Neuromagnetic evidence of a dynamic excitation pattern generating the N100 auditory response. *Electroencephalogr Clin Neurophysiol*, 77: 237-40, 1990.

ROTHENBERGER A, BLANZ B, und LEHMKUHL G. What happens to electrical brain activity when anorectic adolescents gain weight? *Eur Arch Psychiatry Clin Neurosci*, 240: 144-7, 1991.

SALOMON RM, MILLER HL, DELGADO PL, und CHARNEY D. The use of tryptophan depletion to evaluate central serotonin function in depression and other neuropsychiatric disorders. *Int Clin Psychopharmacol*, 8 Suppl 2: 41-6, 1993.

SAMS M, KAUKORANTA E, HAMALAINEN M, und NAATANEN R. Cortical activity elicited by changes in auditory stimuli: Different sources for the magnetic N100M and mismatch responses. *Psychophysiology*, 28: 21-9, 1991.

SCHALLING D, ASBERG M, EDMAN G, und LEVANDER S. Impulsivity, nonconformity and sensation seeking as related to biological markers for vulnerability. *Clinical Neuropharmacology*, 7 (Suppl 1): 746-747, 1984.

SCHERG M. Fundamentals of dipole source potential analysis. In Grandori F, Hoke M, Romani GL (eds), Auditory evoked magnetic fields and electric potentials. *Adv Audiology*, 6: 40-69, 1990.

SCHERG M. Akustisch Evozierte Potentiale - Grundlagen, Entstehungsmechanismen, Quellenmodell. *Stuttgart: Kohlhammer*, 1991.

SCHERG M und VON CRAMON D. Two bilateral sources of the late AEP as identified by a spatio-temporal dipole model. *Electroencephalogr Clin Neurophysiol*, 62: 32-44, 1985.

SCHERG M und VON CRAMON D. Dipole source potentials of the auditory cortex in normal subjects and in patients with temporal lobe lesions. In: Grandori F, Hoke M, Romani GL (eds.) Auditory evoked magnetic fields and electric potentials. *Adv Audiology*, 6: 165-193, 1990.

SCHWARTZ K, WEIZMAN A, und REHAVI M. Decreased platelet vesicular monoamine transporter density in habitual smokers. *European Neuropsychopharmacology*, 15: 235-238, 2005.

SEIFRITZ E, BAUMANN P, MULLER MJ, ANNEN O, AMEY M, HEMMETER U, HATZINGER M, CHARDON F, und HOLSBOER-TRACHSLER E. Neuroendocrine effects of a 20-mg citalopram infusion in healthy males. A placebo-controlled evaluation of citalopram as 5-HT function probe. *Neuropsychopharmacology*, 14: 253-63, 1996.

SENKOWSKI D, LINDEN M, ZUBRAGEL D, BAR T, und GALLINAT J. Evidence for disturbed cortical signal processing and altered serotonergic neurotransmission in generalized anxiety disorder. *Biol Psychiatry*, 53: 304-14, 2003.

SIEVER LJ, KAHN RS, LAWLOR BA, TRESTMAN RL, LAWRENCE TL, und COCCARO EF. Critical issues in defining the role of serotonin in psychiatric disorders. *Pharmacol Rev*, 43: 509-25, 1991.

SILLITO AM und KEMP JA. Cholinergic modulation of the functional organization of the cat visual cortex. *Brain Res*, 289: 143-55, 1983.

SILVER H, BLACKER M, WELLER MP, und LERER B. Treatment of chronic schizophrenia with cyproheptadine. *Biol Psychiatry*, 25: 502-4, 1989.

SINIATCHKIN M, KROPP P, NEUMANN M, GERBER W, und STEPHANI U. Intensity dependence of auditory evoked cortical potentials in migraine families. *Pain*, 85: 247-54, 2000.

SITARAM N, BUCHSBAUM MS, und GILLIN JC. Physostigmine analgesia and somatosensory evoked responses in man. *Eur J Pharmacol*, 42: 285-90, 1977.

SMITH GS, MA Y, DHAWAN V, GUNDUZ H, CARBON M, KIRSHNER M, LARSON J, CHALY T, BELAKHLEFF A, KRAMER E, GREENWALD B, KANE JM, LAGHRISSE-THODE F, POLLOCK BG, und EIDELBER D. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. *Synapse*, 45: 105-12, 2002.

TARKKA IM, STOKIC DS, BASILE LF, und PAPANICOLAOU AC. Electric source localization of the auditory P300 agrees with magnetic source localization. *Electroencephalogr Clin Neurophysiol*, 96: 538-45, 1995.

TAUSCHER J, PIRKER W, DE ZWAAN M, ASENBAUM S, BRUCKE T, und KASPER S. In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. *Eur Neuropsychopharmacol*, 9: 177-9, 1999.

TREPEL M. Neuroanatomie - Struktur und Funktion. *Urban & Fischer*, 1999.

TUCHTENHAGEN F, DAUMANN J, NORRA C, GOBBELE R, BECKER S, PELZ S, SASS H, BUCHNER H, und GOUZOULIS-MAYFRANK E. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. *Neuropsychopharmacology*, 22: 608-17, 2000.

VAN KEMPEN G, ZITMAN F, LINSSEN A, und EDELBROCK P. Biochemical measures in patients with a somatoform pain disorder, before, during, and after treatment with amitriptylin with or without flupentixol. *Biol Psychiatry*, 31: 670-680, 1992.

VAN PRAAG HM. CSF 5-HIAA and suicide in non-depressed schizophrenics. *Lancet*, 2: 977-8, 1983.

VAUGHAN H und AREZZO J. The neural basis of event-related potentials. In *Picton TW (ed), Human Event-Related Potentials, EEG Handbook*, 3: pp 45-96, 1988.

VON KNORRING L. Effect of imipramine and zimelidine on the augmenting-reducing response of visual evoked potentials in healthy volunteers. *Adv Biol Psychiatry*, 9: 81-86, 1982.

VON KNORRING L, ESPVALL M, und PERRIS C. Averaged evoked responses, pain measures, and personality variables in patients with depressive disorders. *Acta Psychiatr Scand Suppl*, 255: 99-108, 1974.

VON KNORRING L und JOHANSSON F. Changes in the augments-reducer tendency and in pain measures as a result of treatment with a serotonin-reuptake inhibitor--zimelidine. *Neuropsychobiology*, 6: 313-8, 1980.

VON KNORRING L, JOHANSSON F, und ALMAY B. Augmenting / reducing response in visual evoked potentials with chronic pain syndromes. *Adv Biol Psychiatry*, 4: 55-62, 1980.

VON KNORRING L und PERRIS C. Biochemistry of the augmenting-reducing response in visual evoked potentials. *Neuropsychobiology*, 7: 1-8, 1981.

WANG W, TIMSIT-BERTHIER M, und SCHOENEN J. Intensity dependence of auditory evoked potentials is pronounced in migraine: An indication of cortical potentiation and low serotonergic neurotransmission? *Neurology*, 46: 1404-9, 1996.

WEGENER G, LINNET K, ROSENBERG R, und MORK A. The effect of acute citalopram on extracellular 5-HT levels is not augmented by lithium: An in vivo microdialysis study. *Brain Res*, 871: 338-42, 2000.

WESTENBERG IS und WEINBERGER NM. Evoked potential decrements in auditory cortex. II. Critical test for habituation. *Electroencephalogr Clin Neurophysiol*, 40: 356-69, 1976.

WESTER P, BERGSTROM U, ERIKSSON A, GEZELIUS C, HARDY J, und WINBLAD B. Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. *J Neurochem*, 54: 1148-56, 1990.

WILLEIT M, PRASCHAK-RIEDER N, NEUMEISTER A, PIRKER W, ASENBAUM S, VITOUCH O, TAUSCHER J, HILGER E, STASTNY J, BRUCKE T, und KASPER S. [123I]-beta-CIT SPECT

imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. *Biol Psychiatry*, 47: 482-9, 2000.

WILLIAMS WA, SHOAF SE, HOMMER D, RAWLINGS R, und LINNOILA M. Effects of acute tryptophan depletion on plasma and cerebrospinal fluid tryptophan and 5-hydroxyindoleacetic acid in normal volunteers. *J Neurochem*, 72: 1641-7, 1999.

WOLPAW JR. Single unit activity vs. Amplitude of the epidural evoked potential in primary auditory cortex of awake cats. *Electroencephalogr Clin Neurophysiol*, 47: 372-6, 1979.

YAMAMOTO T, WILLIAMSON SJ, KAUFMAN L, NICHOLSON C, und LLINAS R. Magnetic localization of neuronal activity in the human brain. *Proc Natl Acad Sci U S A*, 85: 8732-6, 1988.

ZHOU FM und HABLITZ JJ. Activation of serotonin receptors modulates synaptic transmission in rat cerebral cortex. *J Neurophysiol*, 82: 2989-99, 1999.

ZUCKERMAN M. P-impulsive sensation seeking and its behavioral, psychophysiological and biochemical correlates. *Neuropsychobiology*, 28: 30-6, 1993.